HC Wainwright & Co. Affirms Buy Rating for ProMIS Neurosciences, Keeps $4 Price Target Intact
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 21 2025
0mins
Should l Buy PMN?
Source: Benzinga
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PMN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PMN
Wall Street analysts forecast PMN stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 12.880
Low
18.00
Averages
29.33
High
35.00
Current: 12.880
Low
18.00
Averages
29.33
High
35.00
About PMN
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Promis Neurosciences Plans to Raise $200M
- Funding Initiative: Promis Neurosciences has announced a shelf prospectus to raise up to $200 million through various securities offerings, including common shares, preferred shares, subscription receipts, debt securities, warrants, and units, aimed at enhancing the company's financial flexibility and market competitiveness.
- Diverse Securities Offering: The securities may be sold individually or in combination, demonstrating the company's flexibility in its financing strategy, allowing it to adjust the offering structure based on market demand and investor interest, thereby maximizing the effectiveness of the fundraising.
- Market Reaction Outlook: The market holds a cautiously optimistic view on Promis Neurosciences' funding plan, which is expected to provide essential financial support for the company's future R&D and operations, aiding its innovation and development in the neuroscience field.
- Strategic Implications: This funding initiative not only strengthens Promis Neurosciences' capital base but also secures financial backing for future clinical trials and product development, further driving the company's growth and market share expansion in the biopharmaceutical industry.
See More
ProMIS Neurosciences Reports 2025 Financial Results and Pipeline Updates
- Financial Performance: ProMIS Neurosciences reported a net loss of $39.72 million for FY2025, translating to a loss of $22.61 per share, a stark contrast to last year's net income of $2.78 million and earnings of $2.63 per share, indicating significant challenges in R&D investment that may impact future funding capabilities.
- Cash Position: As of December 31, 2025, the company had $6.1 million in cash, and following a private placement in February 2026 that raised $75.5 million, these resources are expected to fund operations through 2027, ensuring the continuation of critical clinical trials.
- Clinical Trial Progress: Following encouraging results from the Phase 1a trial of PMN310 in healthy volunteers, ProMIS initiated the PRECISE-AD Phase 1b clinical trial in Alzheimer's patients, successfully enrolling 144 participants, exceeding the target of 128, reflecting strong market interest in the therapy.
- Market Potential: According to Grand View Research, the global Alzheimer's therapeutics market was estimated at $4.05 billion in 2022 and is projected to reach $15.19 billion by 2030, growing at a CAGR of 19.99%, presenting substantial commercial opportunities for ProMIS's product development.
See More
PROMIS NEUROSCIENCES INC MAY ISSUE SECURITIES WORTH UP TO $200 MILLION, ACCORDING TO SEC FILING
Investment Announcement: PROMIS Neurosciences is offering securities worth up to $200 million.
Purpose of Funding: The funds are intended to support the company's ongoing research and development efforts.
See More
ProMIS Neurosciences Reports FY Losses Exceeding Expectations
- Earnings Miss: ProMIS Neurosciences reported a FY GAAP EPS of -$22.61, missing expectations by $2.57, indicating significant challenges in profitability that could undermine investor confidence.
- Market Reaction: The disappointing earnings report may pressure ProMIS's stock price, prompting investors to monitor subsequent market dynamics and the company's response strategies to assess future investment risks.
- Historical Financial Data: Historical financial data indicates persistent underperformance in profitability for ProMIS, reflecting high costs in R&D and marketing that could lead to long-term financial instability.
- Quant Rating Analysis: Seeking Alpha's quant rating on ProMIS reveals a cautious market sentiment regarding its future performance, necessitating close attention to the company's strategic adjustments and changes in the market environment.
See More
PROMIS NEUROSCIENCES RELEASES 2025 FULL YEAR FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS
Financial Results Announcement: PROMIS Neurosciences has released its financial results for the year 2025, detailing its performance and financial health.
Corporate Highlights: The announcement includes key corporate highlights that showcase the company's achievements and strategic developments over the past year.
See More
Phoenix Mecano Valued at CHF 769, Currently 44% Undervalued
- Intrinsic Value Assessment: Utilizing a two-stage discounted cash flow model, Phoenix Mecano's intrinsic value is estimated at CHF 769, indicating a 44% undervaluation compared to its current share price of CHF 434, reflecting conservative market expectations for future cash flows.
- Future Cash Flow Forecast: The projected free cash flow is expected to grow annually, starting at €28.3 million in 2026 and reaching €57 million by 2035, indicating strong growth potential in the company's profitability and cash generation capabilities.
- Terminal Value Calculation: The estimated terminal value is €887 million, with a present value of €452 million, demonstrating the company's stable growth potential in the long term despite market volatility and industry cyclicality risks.
- Investment Risk Warning: While the company shows strong dividend performance, it has experienced a decline in earnings over the past year, and revenue growth is expected to be below 20%, necessitating investor attention to these potential risks when assessing investment value.
See More
Promis Neurosciences Plans to Raise $200M
- Funding Initiative: Promis Neurosciences has announced a shelf prospectus to raise up to $200 million through various securities offerings, including common shares, preferred shares, subscription receipts, debt securities, warrants, and units, aimed at enhancing the company's financial flexibility and market competitiveness.
- Diverse Securities Offering: The securities may be sold individually or in combination, demonstrating the company's flexibility in its financing strategy, allowing it to adjust the offering structure based on market demand and investor interest, thereby maximizing the effectiveness of the fundraising.
- Market Reaction Outlook: The market holds a cautiously optimistic view on Promis Neurosciences' funding plan, which is expected to provide essential financial support for the company's future R&D and operations, aiding its innovation and development in the neuroscience field.
- Strategic Implications: This funding initiative not only strengthens Promis Neurosciences' capital base but also secures financial backing for future clinical trials and product development, further driving the company's growth and market share expansion in the biopharmaceutical industry.
See More
ProMIS Neurosciences Reports 2025 Financial Results and Pipeline Updates
- Financial Performance: ProMIS Neurosciences reported a net loss of $39.72 million for FY2025, translating to a loss of $22.61 per share, a stark contrast to last year's net income of $2.78 million and earnings of $2.63 per share, indicating significant challenges in R&D investment that may impact future funding capabilities.
- Cash Position: As of December 31, 2025, the company had $6.1 million in cash, and following a private placement in February 2026 that raised $75.5 million, these resources are expected to fund operations through 2027, ensuring the continuation of critical clinical trials.
- Clinical Trial Progress: Following encouraging results from the Phase 1a trial of PMN310 in healthy volunteers, ProMIS initiated the PRECISE-AD Phase 1b clinical trial in Alzheimer's patients, successfully enrolling 144 participants, exceeding the target of 128, reflecting strong market interest in the therapy.
- Market Potential: According to Grand View Research, the global Alzheimer's therapeutics market was estimated at $4.05 billion in 2022 and is projected to reach $15.19 billion by 2030, growing at a CAGR of 19.99%, presenting substantial commercial opportunities for ProMIS's product development.
See More
PROMIS NEUROSCIENCES INC MAY ISSUE SECURITIES WORTH UP TO $200 MILLION, ACCORDING TO SEC FILING
Investment Announcement: PROMIS Neurosciences is offering securities worth up to $200 million.
Purpose of Funding: The funds are intended to support the company's ongoing research and development efforts.
See More
ProMIS Neurosciences Reports FY Losses Exceeding Expectations
- Earnings Miss: ProMIS Neurosciences reported a FY GAAP EPS of -$22.61, missing expectations by $2.57, indicating significant challenges in profitability that could undermine investor confidence.
- Market Reaction: The disappointing earnings report may pressure ProMIS's stock price, prompting investors to monitor subsequent market dynamics and the company's response strategies to assess future investment risks.
- Historical Financial Data: Historical financial data indicates persistent underperformance in profitability for ProMIS, reflecting high costs in R&D and marketing that could lead to long-term financial instability.
- Quant Rating Analysis: Seeking Alpha's quant rating on ProMIS reveals a cautious market sentiment regarding its future performance, necessitating close attention to the company's strategic adjustments and changes in the market environment.
See More
PROMIS NEUROSCIENCES RELEASES 2025 FULL YEAR FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS
Financial Results Announcement: PROMIS Neurosciences has released its financial results for the year 2025, detailing its performance and financial health.
Corporate Highlights: The announcement includes key corporate highlights that showcase the company's achievements and strategic developments over the past year.
See More
Phoenix Mecano Valued at CHF 769, Currently 44% Undervalued
- Intrinsic Value Assessment: Utilizing a two-stage discounted cash flow model, Phoenix Mecano's intrinsic value is estimated at CHF 769, indicating a 44% undervaluation compared to its current share price of CHF 434, reflecting conservative market expectations for future cash flows.
- Future Cash Flow Forecast: The projected free cash flow is expected to grow annually, starting at €28.3 million in 2026 and reaching €57 million by 2035, indicating strong growth potential in the company's profitability and cash generation capabilities.
- Terminal Value Calculation: The estimated terminal value is €887 million, with a present value of €452 million, demonstrating the company's stable growth potential in the long term despite market volatility and industry cyclicality risks.
- Investment Risk Warning: While the company shows strong dividend performance, it has experienced a decline in earnings over the past year, and revenue growth is expected to be below 20%, necessitating investor attention to these potential risks when assessing investment value.
See More
